Dong-Hoon Jin

Prof. Dong-Hoon Jin

Department of Convergence Medicine, Asan Medicdal Center, University of Ulsan College of Medicine, 88 Olympicro-43gil, Songpa-gu, Seoul, Korea

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2012 in Oncogene
Verified
Journal Article
Open access
PDF file
SHS-W Hong
S-W Hong
SLS-H Lee
S-H Lee
JMJ-H Moon
J-H Moon
JHJ J Hwang
J J Hwang
DKD E Kim
D E Kim
WLWang Jae Lee
Wang Jae Lee
L-ascorbate (L-ascorbic acid, vitamin C) clearly has an inhibitory effect on cancer cells. However, the mechanism underlying differential sensitivity of cancer cells from same tissue to L-ascorbate is yet to be clarified. Here, we demonstrate that L-ascorbate has a selective killing effect, which is influenced by sodium-dependent vitamin C transporter 2 (SVCT-2) in human breast cancer cells. Treatment of human breast cancer cells with L-ascorbate differentially induced cell death, dependent on the SVCT-2 protein level. Moreover, knockdown of endogenous SVCT-2 via RNA interference in breast cancer cells expressing high levels of the protein induced resistance to L-ascorbate treatment, whereas transfection with SVCT-2 expression plasmids led to enhanced L-ascorbate chemosensitivity. Surprisingly, tumor regression by L-ascorbate administration in mice bearing tumor cell xenograft also corresponded to the SVCT-2 protein level. Interestingly, SVCT-2 expression was absent or weak in normal tissues, but strongly detected in tumor samples obtained from breast cancer patients. In addition, enhanced chemosensitivity to L-ascorbate occurred as a result of caspase-independent autophagy, which was mediated by beclin-1 and LC3 II. In addition, treatment with N-acetyl-L-cysteine, a reactive oxygen species (ROS) scavenger, suppressed the induction of beclin-1 and LC3 II, implying that the differential SVCT-2 protein-dependent L-ascorbate uptake was attributable to intracellular ROS induced by L-ascorbate, subsequently leading to autophagy. These results suggest that functional SVCT-2 sensitizes breast cancer cells to autophagic damage by increasing the L-ascorbate concentration and intracellular ROS production and furthermore, SVCT-2 in breast cancer may act as an indicator for commencing L-ascorbate treatment.

18 October 2013 in Cell Death & Differentiation
Verified
Journal Article
Closed access
SHS-W Hong
S-W Hong
JMJ-H Moon
J-H Moon
JKJ-S Kim
J-S Kim
JSJ-S Shin
J-S Shin
KJK-A Jung
K-A Jung
TKTae Won Kim
Tae Won Kim

1 June 2016 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
SJSoo-A. Jung
Soo-A. Jung
DLDae-Hee Lee
Dae-Hee Lee
JMJai-Hee Moon
Jai-Hee Moon
SHSeung-Woo Hong
Seung-Woo Hong
JSJae-Sik Shin
Jae-Sik Shin
WLWang Jae Lee
Wang Jae Lee

6 August 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
JMJai-Hee Moon
Jai-Hee Moon
JSJae-Sik Shin
Jae-Sik Shin
SHSeung-Woo Hong
Seung-Woo Hong
SJSoo-A Jung
Soo-A Jung
IHIh-Yeon Hwang
Ih-Yeon Hwang
TKTae Won Kim
Tae Won Kim
A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer

21 March 2014 in Apoptosis
Verified
Journal Article
Closed access
PDF file
SHSeung-Woo Hong
Seung-Woo Hong
JSJae-Sik Shin
Jae-Sik Shin
JMJai-Hee Moon
Jai-Hee Moon
YKYe-Seul Kim
Ye-Seul Kim
JLJooyoung Lee
Jooyoung Lee
TKTae Won Kim
Tae Won Kim

4 April 2019 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
JMJai-Hee Moon
Jai-Hee Moon
SHSeung-Woo Hong
Seung-Woo Hong
JKJeong Eun Kim
Jeong Eun Kim
JSJae-Sik Shin
Jae-Sik Shin
JKJin-Sun Kim
Jin-Sun Kim
DJDong-Hoon Jin
Dong-Hoon Jin
Mitogen-activated protein kinases (MEK 1/2) are central components of the RAS signalling pathway and are attractive targets for cancer therapy. These agents continue to be investigated in KRAS mutant colon cancer but are met with significant resistance. Clinical investigations have demonstrated that these strategies are not well tolerated by patients. We investigated a biomarker of response for MEK inhibition in KRAS mutant colon cancers by LC-MS/MS analysis. We tested the MEK inhibitor in PIK3CA wild(wt) and mutant(mt) colon cancer cells. In addition, we tested the combinational effects of MEK and TNKS inhibitor in vitro and in vivo. We identified β-catenin, a key mediator of the WNT pathway, in response to MEK inhibitor. MEK inhibition led to a decrease in β-catenin in PIK3CA wt colon cancer cells but not in mt. Tumour regression was promoted by combination of MEK inhibition and NVP-TNS656, which targets the WNT pathway. Furthermore, inhibition of MEK promoted tumour regression in colon cancer patient-derived xenograft models expressing PIK3CA wt. We propose that inhibition of the WNT pathway, particularly β-catenin, may bypass resistance to MEK inhibition in human PIK3CA mt colon cancer. Therefore, we suggest that β-catenin is a potential predictive marker of MEK inhibitor resistance.